ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of “Moderate Buy” by Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has earned an average recommendation of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $175.6667.

A number of equities analysts recently issued reports on ICUI shares. KeyCorp increased their target price on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Piper Sandler increased their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Monday, January 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd.

ICU Medical Stock Down 0.2%

ICUI opened at $149.64 on Friday. The stock’s 50 day moving average price is $148.48 and its 200 day moving average price is $134.18. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. The stock has a market cap of $3.69 billion, a P/E ratio of -482.69 and a beta of 0.79. ICU Medical has a 12 month low of $107.00 and a 12 month high of $165.17.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. The company had revenue of $533.30 million during the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The company’s revenue for the quarter was down 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.59 earnings per share. As a group, research analysts predict that ICU Medical will post 4.11 earnings per share for the current year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 930 shares of the business’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the sale, the vice president directly owned 5,456 shares in the company, valued at approximately $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the sale, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of ICU Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in ICUI. Thrivent Financial for Lutherans lifted its stake in ICU Medical by 1,604.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after purchasing an additional 285,648 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of ICU Medical by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock valued at $803,000 after buying an additional 100 shares in the last quarter. F m Investments LLC lifted its position in shares of ICU Medical by 33.3% during the 4th quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after acquiring an additional 11,608 shares during the last quarter. Equitable Trust Co. lifted its position in shares of ICU Medical by 9.6% during the 4th quarter. Equitable Trust Co. now owns 9,330 shares of the medical instruments supplier’s stock valued at $1,331,000 after acquiring an additional 815 shares during the last quarter. Finally, Allegheny Financial Group bought a new stake in shares of ICU Medical during the 4th quarter worth $214,000. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.